Lenalidomide Mylan

Lenalidomide, the active ingredient in Lenalidomide Mylan, is an immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and myeloid clones. - Multiple Myeloma: improves progression‑free survival and overall response rates in patients who have received prior therapy. - Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and can lead to cytogenetic remission in eligible adults. - Mantle Cell Lymphoma: used in combination regimens to achieve disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: upset stomach often occurring after dosing. - Rash: mild skin eruptions or itching. - Constipation: difficulty passing stool. - Peripheral edema: swelling of extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Severe thrombocytopenia: low platelet counts leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating Lenalidomide, several safety considerations should be reviewed. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolic prophylaxis: assess need for anticoagulation in high‑risk patients. - Renal function: adjust monitoring in patients with impaired kidney function. - Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. - Infection risk: monitor for signs of infection and manage promptly. - Store at ambient temperature: keep tablets below 25°C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations of lenalidomide. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase lenalidomide exposure. - Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects. - Vaccines (live attenuated): reduced efficacy; avoid concurrent administration.